Cefopar2 gm/vial

Cefopar is an extended-spectrum, third-generation cephalosporin antibiotic administered by injection, indicated for the treatment of serious infections caused by susceptible gram-negative organisms (including many strains of Pseudomonas aeruginosa) and some gram-positive organisms. Evidence-based uses include:

• Established/approved uses: Respiratory tract infections (upper and lower), intra-abdominal infections (e.g., peritonitis, cholecystitis), bacteremia/septicemia, skin and skin-structure infections, pelvic inflammatory disease and other infections of the female genital tract, and urinary tract infections caused by susceptible organisms.
• Uses that commonly require combination therapy: Serious Pseudomonas aeruginosa infections and mixed/polymicrobial infections are frequently treated with Cefopar combined with an aminoglycoside or another agent (via separate administration/tubing — see Interaction), guided by culture and susceptibility results.
• Not effective against: Cefopar has no activity against Chlamydia trachomatis; it should not be relied upon for infections known or suspected to be caused by this organism.

Use of Cefopar should be guided by culture and susceptibility testing wherever possible, and reserved for infections where a third-generation cephalosporin with antipseudomonal activity is clinically appropriate.

Each vial of the injectable formulation contains Cefoperazone Sodium equivalent to cefoperazone (commonly available in strengths such as 1 g and 2 g cefoperazone per vial) as a sterile powder for reconstitution into a solution for intravenous or intramuscular injection or infusion. Exact strengths, pack sizes, and diluent recommendations vary by manufacturer; always check the product label of the specific brand dispensed.

Cefopar is a semisynthetic, extended-spectrum third-generation cephalosporin antibiotic for parenteral (intravenous or intramuscular) use. It is distinguished among cephalosporins by a piperazine side chain that confers activity against Pseudomonas aeruginosa and other difficult gram-negative organisms, and by a N-methylthiotetrazole (NMTT) side chain that accounts for certain characteristic adverse effects (disulfiram-like reaction with alcohol, and effects on vitamin K-dependent clotting factors). Unlike most other cephalosporins, Cefopar is eliminated primarily by biliary excretion rather than renal excretion.

Third-generation (extended-spectrum, antipseudomonal) cephalosporin antibiotic — Cefopar

Mechanism of Action

Cefoperazone Sodium exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This weakens the cell wall and leads to bacterial cell lysis and death. Its spectrum of activity extends to many gram-negative organisms (including Pseudomonas aeruginosa) and some gram-positive organisms, but it is inactivated by many extended-spectrum beta-lactamases.

Pharmacokinetics

Following intravenous administration, peak serum concentrations of Cefoperazone Sodium are achieved within about an hour. Protein binding is high (approximately 90%). The elimination half-life is approximately 2 hours in patients with normal hepatic and renal function. Unlike most cephalosporins, Cefoperazone Sodium is eliminated predominantly through biliary excretion into bile, with a smaller fraction (approximately 20–30%) recovered unchanged in urine. This biliary-predominant elimination means hepatic/biliary impairment, rather than renal impairment, is the primary factor requiring dose adjustment (see Dosage and Administration).

Cefopar is for parenteral use only (intravenous or intramuscular); it is not given orally.

• Reconstitute strictly according to the manufacturer's instructions for the specific product and route (IV push, intermittent IV infusion, or deep IM injection) — see Reconstitution.
• Administer by slow intravenous injection over 3–5 minutes, or as an intermittent infusion over 15–60 minutes, depending on the dose and clinical setting.
• For intramuscular injection, use an appropriate diluent (e.g., with lidocaine, per product labeling) and inject deep into a large muscle mass to reduce injection-site pain.
• When Cefopar is co-administered with an aminoglycoside, the two must be given through separate intravenous tubing/sites and not mixed in the same syringe or infusion fluid, as they can inactivate each other in vitro (see Interaction).
• Complete the full prescribed course and do not skip or space out doses beyond what is prescribed, even if symptoms improve.

Clinically significant interactions with Cefopar include:

• Alcohol (disulfiram-like reaction): Cefopar contains an N-methylthiotetrazole (NMTT) side chain that can inhibit aldehyde dehydrogenase, producing a disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia, sweating) with alcohol. Patients should avoid alcohol and alcohol-containing products during treatment and for several days after the last dose.
• Anticoagulants/drugs affecting coagulation (e.g., warfarin, heparin): The same NMTT side chain has been associated with hypoprothrombinemia and vitamin K-dependent clotting factor suppression, which may potentiate the effect of anticoagulants and increase bleeding risk; see Contraindications/Precautions and Warnings.
• Aminoglycosides: Often used together for synergy against Pseudomonas aeruginosa and other organisms, but the two drugs can physically/chemically inactivate each other if mixed; they must be administered through separate intravenous lines and not combined in the same solution or syringe.
• Live bacterial vaccines (e.g., live typhoid vaccine, BCG): Antibiotics including Cefopar may reduce the efficacy of live bacterial vaccines; where possible, avoid administering live bacterial vaccines during antibiotic therapy.

Adverse effects reported with Cefopar include:

• Common: Diarrhea, nausea, vomiting, skin rash, injection-site pain/induration (IM) or phlebitis (IV), and transient elevations in liver enzymes.
• Hematologic: Reversible neutropenia, eosinophilia, and hypoprothrombinemia/bleeding tendency related to the NMTT side chain (see Precautions and Warnings).
• Hypersensitivity reactions: Urticaria, pruritus, and rarely angioedema, bronchospasm, or anaphylaxis; serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely with cephalosporins as a class.
• Gastrointestinal: Clostridioides difficile-associated diarrhea/colitis, which can range from mild to life-threatening (see Precautions and Warnings).
• Alcohol-related reaction: Disulfiram-like reaction if alcohol is consumed during or shortly after treatment (see Interaction).
• Other: Fever, headache, and rarely reversible encephalopathy (more likely with very high doses or in renal/hepatic impairment).

Patients should seek prompt medical attention for signs of a serious allergic reaction, unusual bleeding or bruising, or severe/persistent diarrhea.

Pregnancy: Reproduction studies in animals have not shown evidence of fetal harm at doses several times the human dose, but adequate and well-controlled studies in pregnant women are limited. Cefopar should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: Cefopar is excreted in low concentrations in human milk. Caution is advised when administering Cefopar to a breastfeeding woman; consult a physician, and observe the breastfed infant for possible effects on gut flora (e.g., diarrhea, candidiasis) or sensitization.

• Hypersensitivity: Before starting therapy, ask about prior hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactams (see Contraindications). Discontinue immediately if an allergic reaction occurs.
• Disulfiram-like reaction with alcohol: Cefopar contains an NMTT side chain that can cause a disulfiram-like reaction with alcohol; counsel patients to avoid alcohol and alcohol-containing medicines during treatment and for several days after the last dose.
• Bleeding risk/hypoprothrombinemia: The same side-chain structure has been associated with vitamin K-dependent clotting factor suppression. Monitor coagulation parameters, particularly in malnourished patients, those with renal or hepatic impairment, or those on prolonged therapy; vitamin K supplementation may be considered per clinical judgment.
• Clostridioides difficile-associated diarrhea: As with other antibiotics, Cefopar may cause C. difficile-associated diarrhea and colitis, which can range from mild to life-threatening; evaluate if diarrhea occurs during or after treatment.
• Hepatic/biliary impairment: Cefopar is eliminated primarily via biliary excretion, unlike many other cephalosporins that are mainly renally eliminated; dose reduction and monitoring are important in hepatic dysfunction or biliary obstruction (see Dosage and Administration).
• Antibiotic stewardship: Complete the full prescribed course even if symptoms improve early; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• Superinfection: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi; monitor for signs of superinfection during extended therapy.

Specific data on Cefopar overdosage are limited. Excessive doses may increase the risk of adverse effects such as neuromuscular excitability, encephalopathy or seizures (particularly in patients with renal impairment), bleeding tendency (see Precautions and Warnings), and gastrointestinal disturbances. In the event of suspected overdose, discontinue the drug and seek immediate medical attention or contact emergency services/a poison control center; management is supportive and symptomatic, as Cefopar is not significantly removed by routine hemodialysis.

Store the unreconstituted powder at or below 25°C, protected from light and moisture, and out of reach of children. After reconstitution, follow the product label for stability duration and storage conditions (typically room temperature for a limited number of hours, or refrigerated for a longer period, depending on the diluent used); discard any unused reconstituted solution as directed.

Pregnant women: Use Cefopar only if clearly needed, with physician guidance (see Pregnancy and Lactation).

Breastfeeding women: Use with caution and physician supervision; monitor the infant for gastrointestinal effects (see Pregnancy and Lactation).

Pediatric patients: See Pediatric Uses; formal safety and efficacy data are limited, and use should be guided by a pediatric specialist.

Elderly patients: No specific dose adjustment is generally required based on age alone, but hepatic and renal function should be assessed and monitored, as elderly patients more often have organ function impairment.

Hepatic impairment/biliary obstruction: Requires dose limitation (generally not to exceed 4 g/day) and monitoring, since Cefopar is eliminated mainly through bile (see Dosage and Administration).

Renal impairment: Dose adjustment is generally not required for renal impairment alone, but caution and monitoring are advised when renal and hepatic impairment coexist.

Malnourished patients: Closer monitoring of coagulation status is advised due to increased risk of hypoprothrombinemia (see Precautions and Warnings).

Duration of Cefopar therapy depends on the site and severity of infection and clinical response, typically ranging from several days to about two weeks for most infections. Infections due to Streptococcus pyogenes should be treated for a minimum of 10 days to reduce the risk of rheumatic fever or glomerulonephritis. Severe or deep-seated infections (e.g., endocarditis, osteomyelitis, or complicated intra-abdominal infections) may require a longer course as determined by the treating physician. The full prescribed course should be completed even if symptoms improve early.

Cefopar powder for injection must be reconstituted before use, following the manufacturer's instructions for the specific product and intended route:

• For intravenous use: Reconstitute with an appropriate diluent such as Sterile Water for Injection, 5% Dextrose Injection, or 0.9% Sodium Chloride Injection to the concentration specified on the product label; further dilute for intermittent infusion as directed.
• For intramuscular use: Reconstitute with Sterile Water for Injection or, per product labeling, with a diluent containing lidocaine to reduce injection-site pain, to the specified concentration.
• Shake or swirl gently until the powder is completely dissolved; inspect the reconstituted solution visually for particulate matter and discoloration before administration.
• Use the reconstituted solution within the time period stated on the product label (stability varies with diluent and storage temperature — see Storage Conditions); discard any unused portion.

Cephalosporin antibiotic, third-generation, extended-spectrum/antipseudomonal (injectable) — Cefoperazone Sodium

Cefoperazone Sodium inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking the transpeptidation (cross-linking) step of peptidoglycan formation. This results in a weakened, osmotically unstable cell wall, causing bacterial cell lysis and death (bactericidal activity). Its piperazine side chain broadens its spectrum to include Pseudomonas aeruginosa and other gram-negative organisms not covered by earlier cephalosporins.

B

In the original prescribing information, safety and effectiveness of Cefopar in children have not been formally established through controlled pediatric trials. Cefopar has nonetheless been used in pediatric patients, including neonates and infants, in some countries under specialist (pediatric/neonatal) supervision, typically with weight-based dosing (commonly in the range of approximately 50–200 mg/kg/day in divided doses, depending on indication and severity, per local specialist guidance and product labeling) rather than fixed adult dosing. Use in children should occur only under the direction of a physician experienced in pediatric infectious disease management, with attention to hepatic function, coagulation status, and overall clinical response.